

Emily G Mcdonald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7555630/publications.pdf>

Version: 2024-02-01

93
papers

3,449
citations

257450

24
h-index

161849

54
g-index

104
all docs

104
docs citations

104
times ranked

6800
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-invasive diagnosis of <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 23-30.	6.0	22
2	Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. <i>Drug Safety</i> , 2022, 45, 65-74.	3.2	2
3	Outpatient Therapies for COVID-19: How Do We Choose?. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac008.	0.9	18
4	The MedSafer Study: Electronic Decision Support for Deprescribing in Hospitalized Older Adults. <i>JAMA Internal Medicine</i> , 2022, 182, 265.	5.1	44
5	Nirmatrelvir-ritonavir for COVID-19. <i>Cmaj</i> , 2022, 194, E218-E218.	2.0	15
6	Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis. <i>European Respiratory Journal</i> , 2022, 59, 2102921.	6.7	11
7	How generalizable are randomized controlled trials (RCTs) in <i>Staphylococcus aureus</i> bacteremia? A description of the mortality gap between RCTs and observational studies. <i>Clinical Infectious Diseases</i> , 2022, , .	5.8	7
8	<i>Staphylococcus aureus</i> bacteraemia mortality: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1076-1084.	6.0	73
9	Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization. <i>JAMA Network Open</i> , 2022, 5, e226269.	5.9	48
10	What Is the Optimal Follow-up Length for Mortality in <i>Staphylococcus aureus</i> Bacteremia? Observations From a Systematic Review of Attributable Mortality. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac096.	0.9	9
11	Use of Novel Strategies to Develop Guidelines for Management of Pyogenic Osteomyelitis in Adults. <i>JAMA Network Open</i> , 2022, 5, e2211321.	5.9	24
12	Allocated but not treated: the silent 16%. <i>Lancet, The</i> , 2022, 399, 1775.	13.7	0
13	Deprescribing Opportunities for Hospitalized Patients With End-Stage Kidney Disease on Hemodialysis: A Secondary Analysis of the MedSafer Cluster Randomized Controlled Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210987.	1.1	2
14	MedSafer to Support Deprescribing for Residents of Long-Term Care: a Mixed-Methods Study. <i>Canadian Geriatrics Journal</i> , 2022, 25, 175-182.	1.2	1
15	Patient empowerment brochures to increase gabapentinoid deprescribing: protocol for the prospective, controlled before-and-after GABA-WHY trial. <i>CMAJ Open</i> , 2022, 10, E652-E656.	2.4	1
16	Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications. <i>JAMA Network Open</i> , 2022, 5, e2220184.	5.9	13
17	Postpartum Analgesia in New Mothers (PAIN) Study: A Survey of Canadian Obstetricians' Post-Delivery Opioid-Prescribing Practices. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 957-966.e9.	0.7	1
18	Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists Likely Increase Mortality in Critical Care: An Updated Meta-Analysis. <i>American Journal of Medicine</i> , 2021, 134, e184-e188.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e835-e843.	5.8	103
20	Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines. <i>Annals of Epidemiology</i> , 2021, 55, 24-26.	1.9	10
21	Tocilizumab versus the Covid19 tempest: Allâ€™s well that ends well or much ado about nothing?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 158-159.	6.0	2
22	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 104, 671-676.	3.3	21
23	Handheld infrared thermometer to evaluate cellulitis: the HI-TEC study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1814-1819.	6.0	1
24	Proton pump inhibitor use and risk for recurrent <i>Clostridioides difficile</i> infection: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2021, 27, 697-703.	6.0	29
25	Tenofovir-induced osteomalacia with hypophosphataemia. <i>BMJ Case Reports</i> , 2021, 14, e240387.	0.5	1
26	Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis. <i>JAMA Network Open</i> , 2021, 4, e2115352.	5.9	68
27	Treatment-induced neuropathy of diabetes related to abrupt glycemic control. <i>Cmaj</i> , 2021, 193, E1085-E1088.	2.0	4
28	Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1535.	5.1	10
29	The Reply. <i>American Journal of Medicine</i> , 2021, 134, e536-e537.	1.5	0
30	Evaluation of a home-based 7-day infection control strategy for healthcare workers following high-risk exposure to severe acute respiratory coronavirus virus 2 (SARS-CoV-2): A cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1194-1197.	1.8	3
31	Physician Perspectives on Including Pregnant Women in Covidâ€™19 Clinical Trials: Time for a Paradigm Change. <i>Ethics & Human Research</i> , 2021, 43, 19-27.	0.9	2
32	On the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: Current Practice Based on Outdated Evidence. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab545.	0.9	9
33	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa602.	0.9	9
34	Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ</i> , The, 2021, 375, e068060.	6.0	52
35	Spread and scale of an electronic deprescribing software to improve health outcomes of older adults living in nursing homes: study protocol for a stepped wedge cluster randomized trial. <i>Trials</i> , 2021, 22, 763.	1.6	0
36	Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa449.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Radiographic features in investigated for <i>Pneumocystis jirovecii</i> pneumonia: a nested case-control study. <i>BMC Infectious Diseases</i> , 2020, 20, 492.	2.9	10
38	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa500.	0.9	38
39	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 623-631.	3.9	444
40	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19—A Call for Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa350.	0.9	25
41	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020, 17, 491-500.	1.6	56
42	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020, 67, 1201-1211.	1.6	19
43	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 517-525.	27.0	1,081
44	Diagnostic accuracy of serum (1-3)- β -D-glucan for <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1137-1143.	6.0	72
45	Adverse Drug Events in Older Adults: Review of Adjudication Methods in Deprescribing Studies. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1594-1602.	2.6	14
46	An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Canâ€™t Get No) Satisfaction. <i>International Journal of Infectious Diseases</i> , 2020, 98, 216-217.	3.3	18
47	Deprescribing Proton Pump Inhibitors. <i>JAMA Internal Medicine</i> , 2020, 180, 571.	5.1	14
48	Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 425-429.	1.8	3
49	Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1184-1192.	2.6	38
50	Low-Dose TMP-SMX in the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa112.	0.9	19
51	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa130.	0.9	160
52	<scp>COVIDâ€™SAFER</scp>: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1636-1646.	2.6	29
53	Time-Series Analysis of Health Careâ€™Associated Infections in a New Hospital With All Private Rooms. <i>JAMA Internal Medicine</i> , 2019, 179, 1501.	5.1	37
54	An online educational module on transfusion safety and appropriateness for resident physicians: a controlled beforeâ€™after quality-improvement study. <i>CMAJ Open</i> , 2019, 7, E492-E496.	2.4	9

#	ARTICLE	IF	CITATIONS
55	The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1843-1850.	2.6	49
56	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e24-e25.	1.5	1
57	Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	13
58	Retrospective Cohort Study of the Prevalence of Off-label Gabapentinoid Prescriptions in Hospitalized Medical Patients. <i>Journal of Hospital Medicine</i> , 2019, 14, 547-550.	1.4	7
59	Evaluation of a Mobile Application to Enhance Medication Management Following Hospital Discharge: Study Protocol for a Pilot Randomized Controlled Trial. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 1929-1930.	0.3	3
60	EMPOWERing Hospitalized Older Adults to Deprescribe Sedative Hypnotics: A Pilot Study. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1186-1189.	2.6	27
61	Hand hygiene "hall monitors" Leveraging the Hawthorne effect. <i>American Journal of Infection Control</i> , 2018, 46, 706-707.	2.3	4
62	Association of Lower Diagnostic Yield With High Users of CT Pulmonary Angiogram. <i>JAMA Internal Medicine</i> , 2018, 178, 412.	5.1	20
63	CS-36...Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
64	Severe pet-transmitted zoonosis in a patient with a compromised immune system. <i>Cmaj</i> , 2018, 190, E1332-E1336.	2.0	3
65	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43
66	Rates of Overtreatment and Treatment-Related Adverse Effects Among Patients With Subsegmental Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2018, 178, 1272.	5.1	30
67	Screening swabs surpass traditional risk factors as predictors of MRSA bacteremia. <i>BMC Infectious Diseases</i> , 2018, 18, 270.	2.9	8
68	Monitoring of Systemic Lupus Erythematosus Pregnancies: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 1477-1490.	2.0	14
69	MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2018, 77, 489-495.	3.3	27
70	Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial. <i>American Journal of Medicine</i> , 2018, 131, 1228-1233.e1.	1.5	22
71	"Explainable" Weight Loss. <i>JAMA Internal Medicine</i> , 2017, 177, 420.	5.1	1
72	Missed Opportunities for Deprescription. <i>JAMA Internal Medicine</i> , 2017, 177, 1028.	5.1	2

#	ARTICLE	IF	CITATIONS
73	Mindfulness-Based Laboratory Reduction: Reducing Utilization Through Trainee-Led Daily "Time Outs"™. American Journal of Medicine, 2017, 130, e241-e244.	1.5	21
74	Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. Cmaj, 2017, 189, E1188-E1191.	2.0	6
75	Inpatient Z-drug use commonly exceeds safe dosing recommendations. PLoS ONE, 2017, 12, e0177645.	2.5	2
76	At the Crossroad with Morbidity and Mortality Conferences: Lessons Learned through a Narrative Systematic Review. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-11.	1.9	28
77	Using MRSA Screening Tests to Predict Methicillin Resistance in Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
78	Off-label Use of Quetiapine in Medical Inpatients and Postdischarge. JAMA Internal Medicine, 2016, 176, 1390.	5.1	18
79	A point prevalence study of urinary catheter use among teaching hospitals with and without reduction programs. Journal of Hospital Medicine, 2016, 11, 799-800.	1.4	2
80	Costs of Inpatient Medications: Do Dispensing and Nursing Fees Lead to Overestimates?"Reply. JAMA Internal Medicine, 2016, 176, 1882.	5.1	0
81	Extracorporeal membrane oxygenation for the treatment of severe refractory hantavirus cardiopulmonary syndrome. Cmaj, 2016, 188, E528-E530.	2.0	2
82	Insomnia in the Hospital"Not Just a Bad Dream. JAMA Internal Medicine, 2016, 176, 1253.	5.1	3
83	Using MRSA Screening Tests To Predict Methicillin Resistance in Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2016, 60, 7444-7448.	3.2	14
84	Pattern of Inpatient Laxative Use. JAMA Internal Medicine, 2016, 176, 1216.	5.1	19
85	Premature cardiovascular disease following a history of hypertensive disorder of pregnancy. International Journal of Cardiology, 2016, 219, 9-13.	1.7	20
86	Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. Cmaj, 2016, 188, 657-662.	2.0	29
87	Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before-after study using education paired with a web-based quality improvement tool. Journal of Hospital Medicine, 2015, 10, 281-286.	1.4	34
88	Ezetimibe Use Remains Common Among Medical Inpatients. American Journal of Medicine, 2015, 128, 193-195.	1.5	2
89	Clinician Understanding of Cholesterol Treatment Guidelines. JAMA - Journal of the American Medical Association, 2015, 313, 2381.	7.4	3
90	Treatment for Clostridium difficile Infection in Adults. JAMA - Journal of the American Medical Association, 2015, 313, 1974.	7.4	3

#	ARTICLE	IF	CITATIONS
91	Reduction of Central Venous Catheter Use in Medical Inpatients Through Regular Physician Audits Using an Online Tool. JAMA Internal Medicine, 2015, 175, 1232.	5.1	2
92	Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Internal Medicine, 2015, 175, 784.	5.1	184
93	Inpatient Attire. JAMA Internal Medicine, 2014, 174, 1865.	5.1	11